Stock Price Quote

SUN PHARMACEUTICAL INDUSTRIES LTD.

NSE : SUNPHARMABSE : 524715ISIN CODE : INE044A01036Industry : Pharmaceuticals & DrugsHouse : Sun Pharma
BSE1749.507 (+0.4 %)
PREV CLOSE ( ) 1742.50
OPEN PRICE ( ) 1745.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 18408
TODAY'S LOW / HIGH ( )1727.90 1753.50
52 WK LOW / HIGH ( )1376.75 1960.2
NSE1749.807.8 (+0.45 %)
PREV CLOSE( ) 1742.00
OPEN PRICE ( ) 1751.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1749.80 (522)
VOLUME 1371545
TODAY'S LOW / HIGH( ) 1727.30 1753.00
52 WK LOW / HIGH ( )1377.2 1960.35
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 01-03 1993
Management Info
Dilip S Shanghvi - Chairman Dilip S Shanghvi - Managing Director
Registered Office

Address Sun Pharma Advanced Research Centre (S P A R C),Tandalja, ,
Vadodara,
Gujarat-390012

Phone 0265- 5515500 / 5515600 / 5515700

Email secretarial@sunpharma.com

Website www.sunpharma.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

03Feb Sun Pharmaceutical rises on reporting
Sun Pharmaceutical Industries is currently trading at Rs. 1766.10, up by..
01Feb Sun Pharma rises on reporting 14% surg
Sun Pharmaceutical is currently trading at Rs. 1765.00, up by 21.90 poin..
31Jan Sun Pharmaceutical reports 14% surge i
Sun Pharmaceutical Industries has reported results for third quarter end..
22Jan Sun Pharma trades in green on the bour
Sun Pharmaceutical Industries is currently trading at Rs. 1801.50, up by..
16Jan Sun Pharmaceutical Industries informs
Sun Pharmaceutical Industries has informed that TARO Pharmaceuticals Inc..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit11810.528581.8
Gross Profit 12649.3 34496.5
Operating Profit 17718.660533.7
Net Sales 61918.1202751.7

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  29796.40 (2.39%)
M.Cap ( in Cr)63315.27
Torrent Pharma (BSE)
peergroup  3259.40 (3.10%)
M.Cap ( in Cr)110312.91
Aarti Pharmalabs (BSE)
peergroup  740.55 (8.93%)
M.Cap ( in Cr)6711.31
Astrazeneca Pharma I (BSE)
peergroup  7639.45 (0.60%)
M.Cap ( in Cr)19098.63
Caplin Point Lab (BSE)
peergroup  2216.50 (2.11%)
M.Cap ( in Cr)16847.99

Shareholding Pattern

NON-INSTITUTION 8.93%
PROMOTERS 54.48%
FI/BANKS/INSURANCE 4.79%
MUTUAL FUNDS/UTI 12.24%
GOVERNMENT 0%
FII 0%

About Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd. was incorporated in the year 1993. Its today's share price is 1749.5. Its current market capitalisation stands at Rs 419763.65 Cr. In the latest quarter, company has reported Gross Sales of Rs. 202751.7 Cr and Total Income of Rs.208286.5 Cr. The company's management includes Anoop Deshpande, Rolf Hoffmann, Sanjay Asher, Rama Bijapurkar, Gautam Doshi, Sudhir V Valia, Aalok Shanghvi, Pawan Goenka, Dilip S Shanghvi, Dilip S Shanghvi.

It is listed on the BSE with a BSE Code of 524715 , NSE with an NSE Symbol of SUNPHARMA and ISIN of INE044A01036. It's Registered office is at Sun Pharma Advanced Research Centre (S P A R C),Tandalja, Vadodara-390012, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloittee Haskins & Sells, Price Waterhouse, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.